Cardiometabolic And Neuropathic Tailwinds Will Drive Major Upside Over The Long Term

Catalysts

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing and partnering innovative medicines for cardiometabolic diseases and neuropathic pain.

What are the underlying business or industry changes driving this perspective?

• Acceleration of global cardiovascular disease and heart failure, together with a growing recognition of hypertrophic cardiomyopathy, positions sotagliflozin and the SONATA-HCM program to address a rapidly expanding patient pool. This may support potential step function changes in product revenue and operating leverage.
• Heightened political and regulatory push to replace opioids with safer chronic pain therapies, exemplified by new U.S. legislation and FDA draft guidance, directly favors pilavapadin as a late stage, non-opioid neuropathic pain candidate. This creates a path to potential future sales and may support structurally higher net margins.
• Surging global investment and patient demand in obesity treatment provides a tailwind for LX9851 under Lexicon's partnership with Novo Nordisk. In this context, potential milestones and royalty streams could diversify revenue and affect long-run earnings power.
• Rising acceptance of SGLT inhibitors as cardiometabolic therapies, combined with sotagliflozin's differentiation in HCM, HFpEF and type 1 diabetes, may support pricing and usage that can influence top line growth and gross margin mix over time.
• An ongoing shift in biopharma toward capital efficient, partnership heavy R&D models aligns with Lexicon's lean expense base, third party funded evidence generation and global alliances. This may help moderate operating expense growth and influence the path toward profitability.

Assumptions

This narrative explores a more optimistic perspective on Lexicon Pharmaceuticals compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Lexicon Pharmaceuticals's revenue will decrease by 5.7% annually over the next 3 years.
• The bullish analysts are not forecasting that Lexicon Pharmaceuticals will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Lexicon Pharmaceuticals's profit margin will increase from -96.8% to the average US Pharmaceuticals industry of 20.9% in 3 years.
• If Lexicon Pharmaceuticals's profit margin were to converge on the industry average, you could expect earnings to reach $12.4 million (and earnings per share of $0.03) by about December 2028, up from $-68.6 million today.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 218.2x on those 2028 earnings, up from -6.5x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 19.7x.
• The bullish analysts expect the number of shares outstanding to grow by 0.53% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.96%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Lexicon remains an R&D focused company with no clear path to profitability as its current revenue base is heavily dependent on finite Novo Nordisk licensing milestones and modest INPEFA product sales. If late stage programs such as pilavapadin Phase III in DPNP or SONATA in HCM fail or are delayed, the company could see revenue stall while operating costs for ongoing trials continue, pressuring earnings and extending net losses.
• The obesity and chronic pain markets are highly competitive and capital intensive, and Lexicon is relying on partners like Novo Nordisk for LX9851 and an as yet unsigned partner for pilavapadin to fund pivotal development. Any slowdown in partner commitment, reprioritization toward competing internal assets or unfavorable deal terms could constrain trial execution and commercialization, limiting long term revenue growth and margin expansion.
• Regulatory outcomes for sotagliflozin are uncertain, with Zynquista in type 1 diabetes already having received a complete response letter and now relying on STENO exposure data to address diabetic ketoacidosis concerns. Any further FDA pushback on safety or trial design, or a narrower than expected label in heart failure or HCM, could cap pricing power and patient uptake, reducing expected revenue and depressing net margins.
• The company’s strategic shift to a lean, efficiency driven, largely virtual commercial model for INPEFA and potential future launches in niche cardiometabolic indications may not be sufficient to compete against larger incumbents and new CMIs that benefit from broader sales infrastructures and REMS driven positioning. This could limit sotagliflozin’s share in heart failure and HCM and prevent Lexicon from achieving the anticipated operating leverage and earnings improvement.
• Cash, short term investments and restricted cash have already declined from $238 million at year end 2024 to $145 million by the third quarter of 2025. With ongoing investment needs in SONATA, Zynquista resubmission work and pre launch activities, Lexicon may need to raise additional capital or accept dilutive or royalty heavy partnerships if milestones slip or trials expand, which would weigh on per share earnings and may offset any future revenue gains.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Lexicon Pharmaceuticals is $6.0, which represents up to two standard deviations above the consensus price target of $2.88. This valuation is based on what can be assumed as the expectations of Lexicon Pharmaceuticals's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $6.0, and the most bearish reporting a price target of just $1.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2028, revenues will be $59.5 million, earnings will come to $12.4 million, and it would be trading on a PE ratio of 218.2x, assuming you use a discount rate of 7.0%.
  
• Given the current share price of $1.23, the analyst price target of $6.0 is 79.5% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.